(BE), a Hyderabad, India-based vaccines and pharmaceutical company, Technologies Corporation (Dynavax), a U.S.-based vaccine-focused biopharmaceutical company, and Baylor College of Medicine today announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate following approval from the Drugs Controller General of India.
The vaccine candidate includes an antigen in-licensed from , Baylor College of Medicine’s integrated commercialization team, along with Dynavax’s advanced adjuvant, CpG 1018, to boost immune response.
BE’s Phase I/II clinical trial will evaluate the safety and immunogenicity, or ability to induce an immune response, of the vaccine candidate. The candidate consists of the receptor binding domain of the SARS-CoV-2 spike protein at three dose levels adjuvanted with CpG 1018 plus alum, in about 360 healthy subjects ages 18 to 65 years. The vaccination schedule consists of two doses for each study participant, administered via intramuscular injection 28 days apart.
The results of this clinical trial are expected to be available by February 2021.
“The transition of our vaccine candidate into human trials is an important milestone and exemplifies a successful transfer of technology with BE that could lead to a safe, effective and affordable vaccine,” said , associate dean of the at Baylor College of Medicine and co-director of .
“This vaccine represents an urgent biotechnology innovation for ensuring health equity and combating the COVID-19 pandemic,” said , professor and dean of the ³Ô¹ÏÍøÕ¾ School of Tropical Medicine at Baylor and co-director of Texas Children’s Hospital Center for Vaccine Development.
“We are very happy indeed to transition our potential vaccine candidate to clinical trials and offer one more potential option for the prophylaxis of COVID-19,” said Mahima Datla, managing director of Biological E. Limited.
“We are proud to contribute CpG 1018 to support development of an adjuvanted vaccine to prevent COVID-19. CpG 1018’s potential to boost the immune response to produce more antibodies and longer lasting immunity may also minimize the dose of antigen needed, enabling vaccination of a greater number of people,” said , chief executive officer of Dynavax.
